Blood test may reveal who will beat liver cancer
NCT ID NCT05263830
Summary
This study aims to find out if measuring a specific protein in the blood (called GPC-3) can help doctors predict which patients with advanced liver cancer will respond best to a standard immunotherapy drug combination. Researchers will track 240 patients receiving the drugs atezolizumab and bevacizumab, checking their blood levels of GPC-3 and other markers over time. The goal is to learn if these blood tests can forecast treatment effectiveness and patient survival, helping future patients get more personalized care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière
RECRUITINGParis, 75013, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.